JNCEinactive

Jounce Therapeutics, Inc.

Healthcare·Oncology·Phase 2

OncologyImmunology

Jounce Therapeutics, Inc. (JNCE): 6 pipeline candidates. Updated within the last hour.

7.9/10

BioSniper Score

2-factor signal · derived from public data

Cash RunwayN/A

N/A

Financial HealthN/A

N/A

Pipeline Maturity6.0

Lead: Phase 2

Pipeline Breadth9.8

6 candidates

Catalyst MomentumN/A

N/A

Insider SignalN/A

N/A

A transparent, data-derived signal for Jounce Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

—

Cash

—

Quarterly Burn

—

Runway

—

Revenue

—

Pipeline (6 candidates)

Drug	Phase	Indication
gs-1811	Phase 1	Solid tumors
jtx-1484	Preclinical	Solid tumors
jtx-2134	Preclinical	Solid tumors
jtx-8064	Phase 2	Solid tumors (PD-(L)1-inhibitor resistant or sensitive)
pimivalimab	Phase 1	Solid tumors (in combination)
vopratelimab	Phase 2	Immunotherapy-naive second-line NSCLC

·CEO: Richard Murray, Ph.D.

Frequently asked questions

How many drug candidates are in Jounce Therapeutics, Inc.'s pipeline?

Jounce Therapeutics, Inc. (JNCE) has 6 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.

What is Jounce Therapeutics, Inc.'s lead drug candidate?

Jounce Therapeutics, Inc.'s most advanced tracked candidate is gs-1811 (Phase 1) for Solid tumors.

Who is the CEO of Jounce Therapeutics, Inc.?

Richard Murray, Ph.D. is the chief executive officer of Jounce Therapeutics, Inc. (JNCE).

Get the full picture on Jounce Therapeutics, Inc.

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.

Start Free Analysis Browse Calendar